MASH outcomes master protocol including tirzepatide begins recruiting

A phase 3 master protocol trial called SYNERGY-Outcomes has begun recruiting patients with metabolic dysfunction-associated steatotic liver disease, or MASLD, according to its registration on ClinicalTrials.gov ^[1]. The study, listed under identifier NCT07165028, is designed to enroll about 4,500 participants and will test tirzepatide along with other agents under a single protocol structure ^[1].

The trial's main goal is different from most earlier liver studies. Its primary endpoint is a measure of major adverse liver outcomes, rather than a surrogate marker like liver fat content or fibrosis stage on a biopsy ^[1]. Estimated primary completion is set for August 2030 ^[1]. That is a long timeline, reflecting the fact that serious liver outcomes such as liver failure, transplant, or liver-related death take years to accumulate in a study population, even a large one.

This distinction matters because of what came before it. A phase 2 trial known as SYNERGY-NASH tested tirzepatide in patients with metabolic dysfunction-associated steatohepatitis, or MASH, the more advanced form of the disease, but it was not built to answer whether the drug lowers the risk of actual liver-related health crises ^[1]. SYNERGY-Outcomes is described as the outcomes-level study meant to fill that gap ^[1]. In plain terms, phase 2 data can show a drug improves liver scans or biopsy results, but only a large, long outcomes trial like this one can show whether that improvement translates into fewer people going on to liver failure, needing a transplant, or dying from liver disease.

Why it matters for patients

For people currently taking tirzepatide (sold as Mounjaro or Zepbound) or considering it, this trial does not change anything about current prescribing or approval status right away. The study is still in the recruiting phase, and its primary completion is not expected until August 2030 ^[1]. Results, and any regulatory decisions based on those results, would come well after that.

What this trial represents is a shift toward asking a harder, more clinically meaningful question about GLP-1 and dual-agonist drugs like tirzepatide: not just whether they shrink fat in the liver, but whether they actually prevent the liver complications that can shorten life or require a transplant. Patients with MASLD or MASH who are weighing treatment options may eventually benefit from having outcomes data instead of only surrogate marker data, but that benefit is years away based on the current timeline ^[1].

It is not yet known from the available source how many trial sites are involved, what specific comparator arms or doses are being used within the master protocol, or which other agents beyond tirzepatide are included, since the ClinicalTrials.gov record excerpt available does not spell out that detail ^[1].

What happens next

The trial is currently in the recruiting phase, according to its ClinicalTrials.gov listing ^[1]. Estimated primary completion, when the main liver-outcomes data would be assessed, is projected for August 2030 ^[1]. Enrollment of the full target of roughly 4,500 participants will need to happen before that data can mature, and no interim readouts or additional milestones are specified in the available record ^[1].